SillaJen
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SillaJen is a South Korean biotech company, listed on KOSDAQ, that develops experimental cancer treatments, including engineered viruses designed to infect and destroy tumour cells while stimulating the body's own immune system, and small-molecule drugs that disrupt cancer-cell division.
It also has a pharmaceutical division that develops and supplies generic and improved versions of injectable prescription medicines not previously available in Korea. The company runs two distinct business lines: an oncology drug-development programme and a commercial pharmaceutical operation.
Summary is AI-generated and may contain errors · figures from DART filings
SillaJen in five facts
What does SillaJen do?
SillaJen is a South Korean biotech company, listed on KOSDAQ, that develops experimental cancer treatments, including engineered viruses designed to infect and destroy tumour cells while stimulating the body's own immune system, and small-molecule drugs that disrupt cancer-cell division.
Where is SillaJen listed and in which sector?
SillaJen (Korean name: 신라젠) trades under KRX code 215600 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is SillaJen?
Its market capitalisation was US$234.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SillaJen's latest annual revenue and operating profit?
For fiscal year 2025, SillaJen reported revenue of US$7M, an operating loss of US$19.3M and a net loss of US$18.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 134.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureSep 15
- [Amended] Grant of stock optionsSep 3
- [Amended] Grant of stock optionsSep 3
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SillaJen reported consolidated results for FY2025: revenue of US$6.32M (+134.9% year on year), an operating loss of US$17.5M and a net loss of US$16.5M.
Earnings · Feb 5